{"pmid":32434945,"title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","text":["DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.","Science","Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H","32434945"],"abstract":["The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates."],"journal":"Science","authors":["Yu, Jingyou","Tostanoski, Lisa H","Peter, Lauren","Mercado, Noe B","McMahan, Katherine","Mahrokhian, Shant H","Nkolola, Joseph P","Liu, Jinyan","Li, Zhenfeng","Chandrashekar, Abishek","Martinez, David R","Loos, Carolin","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Chen, Yuezhou","Zuiani, Adam","N Lelis, Felipe J","Travers, Meghan","Habibi, Shaghayegh","Pessaint, Laurent","Van Ry, Alex","Blade, Kelvin","Brown, Renita","Cook, Anthony","Finneyfrock, Brad","Dodson, Alan","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kirilova, Marinela","Kordana, Nicole","Lin, Zijin","Maxfield, Lori F","Nampanya, Felix","Nityanandam, Ramya","Ventura, John D","Wan, Huahua","Cai, Yongfei","Chen, Bing","Schmidt, Aaron G","Wesemann, Duane R","Baric, Ralph S","Alter, Galit","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434945","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1126/science.abc6284","topics":["Treatment"],"weight":1,"_version_":1667521393700372481,"score":9.490897,"similar":[{"pmid":32434946,"title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques.","text":["SARS-CoV-2 infection protects against rechallenge in rhesus macaques.","An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.","Science","Chandrashekar, Abishek","Liu, Jinyan","Martinot, Amanda J","McMahan, Katherine","Mercado, Noe B","Peter, Lauren","Tostanoski, Lisa H","Yu, Jingyou","Maliga, Zoltan","Nekorchuk, Michael","Busman-Sahay, Kathleen","Terry, Margaret","Wrijil, Linda M","Ducat, Sarah","Martinez, David R","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Pessaint, Laurent","Van Ry, Alex","Greenhouse, Jack","Taylor, Tammy","Blade, Kelvin","Cook, Anthony","Finneyfrock, Brad","Brown, Renita","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Abbink, Peter","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kordana, Nicole","Li, Zhenfeng","Lifton, Michelle A","Mahrokhian, Shant H","Maxfield, Lori F","Nityanandam, Ramya","Nkolola, Joseph P","Schmidt, Aaron G","Miller, Andrew D","Baric, Ralph S","Alter, Galit","Sorger, Peter K","Estes, Jacob D","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H","32434946"],"abstract":["An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates."],"journal":"Science","authors":["Chandrashekar, Abishek","Liu, Jinyan","Martinot, Amanda J","McMahan, Katherine","Mercado, Noe B","Peter, Lauren","Tostanoski, Lisa H","Yu, Jingyou","Maliga, Zoltan","Nekorchuk, Michael","Busman-Sahay, Kathleen","Terry, Margaret","Wrijil, Linda M","Ducat, Sarah","Martinez, David R","Atyeo, Caroline","Fischinger, Stephanie","Burke, John S","Slein, Matthew D","Pessaint, Laurent","Van Ry, Alex","Greenhouse, Jack","Taylor, Tammy","Blade, Kelvin","Cook, Anthony","Finneyfrock, Brad","Brown, Renita","Teow, Elyse","Velasco, Jason","Zahn, Roland","Wegmann, Frank","Abbink, Peter","Bondzie, Esther A","Dagotto, Gabriel","Gebre, Makda S","He, Xuan","Jacob-Dolan, Catherine","Kordana, Nicole","Li, Zhenfeng","Lifton, Michelle A","Mahrokhian, Shant H","Maxfield, Lori F","Nityanandam, Ramya","Nkolola, Joseph P","Schmidt, Aaron G","Miller, Andrew D","Baric, Ralph S","Alter, Galit","Sorger, Peter K","Estes, Jacob D","Andersen, Hanne","Lewis, Mark G","Barouch, Dan H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434946","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1126/science.abc4776","topics":["Mechanism"],"weight":1,"_version_":1667521393540988928,"score":715.0357},{"pmid":32376603,"title":"Rapid development of an inactivated vaccine candidate for SARS-CoV-2.","text":["Rapid development of an inactivated vaccine candidate for SARS-CoV-2.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 mug or 6 mug per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans.","Science","Gao, Qiang","Bao, Linlin","Mao, Haiyan","Wang, Lin","Xu, Kangwei","Yang, Minnan","Li, Yajing","Zhu, Ling","Wang, Nan","Lv, Zhe","Gao, Hong","Ge, Xiaoqin","Kan, Biao","Hu, Yaling","Liu, Jiangning","Cai, Fang","Jiang, Deyu","Yin, Yanhui","Qin, Chengfeng","Li, Jing","Gong, Xuejie","Lou, Xiuyu","Shi, Wen","Wu, Dongdong","Zhang, Hengming","Zhu, Lang","Deng, Wei","Li, Yurong","Lu, Jinxing","Li, Changgui","Wang, Xiangxi","Yin, Weidong","Zhang, Yanjun","Qin, Chuan","32376603"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 mug or 6 mug per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans."],"journal":"Science","authors":["Gao, Qiang","Bao, Linlin","Mao, Haiyan","Wang, Lin","Xu, Kangwei","Yang, Minnan","Li, Yajing","Zhu, Ling","Wang, Nan","Lv, Zhe","Gao, Hong","Ge, Xiaoqin","Kan, Biao","Hu, Yaling","Liu, Jiangning","Cai, Fang","Jiang, Deyu","Yin, Yanhui","Qin, Chengfeng","Li, Jing","Gong, Xuejie","Lou, Xiuyu","Shi, Wen","Wu, Dongdong","Zhang, Hengming","Zhu, Lang","Deng, Wei","Li, Yurong","Lu, Jinxing","Li, Changgui","Wang, Xiangxi","Yin, Weidong","Zhang, Yanjun","Qin, Chuan"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376603","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/science.abc1932","topics":["Treatment"],"weight":1,"_version_":1666597097311305729,"score":414.41818},{"pmid":32396922,"title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.","text":["Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.","An outbreak of a novel coronavirus, named SARS-CoV-2, causing respiratory disease and a ~2% case fatality rate started in Wuhan, China in December 2019(1,2). Following unprecedented global spread(3), the World Health Organization declared COVID-19 a pandemic on March 11, 2020. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models, where repeated sampling and tissue collection is possible. Here, we show that SARS-CoV-2 causes respiratory disease in infected rhesus macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in bronchoalveolar lavages; in one animal we observed prolonged rectal shedding. Taken together, the rhesus macaque recapitulates moderate disease observed in the majority of human cases. The establishment of the rhesus macaque as a model of COVID-19 will increase our understanding of the pathogenesis of this disease and will aid development and testing of medical countermeasures.","Nature","Munster, Vincent J","Feldmann, Friederike","Williamson, Brandi N","van Doremalen, Neeltje","Perez-Perez, Lizzette","Schulz, Jonathan","Meade-White, Kimberly","Okumura, Atsushi","Callison, Julie","Brumbaugh, Beniah","Avanzato, Victoria A","Rosenke, Rebecca","Hanley, Patrick W","Saturday, Greg","Scott, Dana","Fischer, Elizabeth R","de Wit, Emmie","32396922"],"abstract":["An outbreak of a novel coronavirus, named SARS-CoV-2, causing respiratory disease and a ~2% case fatality rate started in Wuhan, China in December 2019(1,2). Following unprecedented global spread(3), the World Health Organization declared COVID-19 a pandemic on March 11, 2020. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models, where repeated sampling and tissue collection is possible. Here, we show that SARS-CoV-2 causes respiratory disease in infected rhesus macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in bronchoalveolar lavages; in one animal we observed prolonged rectal shedding. Taken together, the rhesus macaque recapitulates moderate disease observed in the majority of human cases. The establishment of the rhesus macaque as a model of COVID-19 will increase our understanding of the pathogenesis of this disease and will aid development and testing of medical countermeasures."],"journal":"Nature","authors":["Munster, Vincent J","Feldmann, Friederike","Williamson, Brandi N","van Doremalen, Neeltje","Perez-Perez, Lizzette","Schulz, Jonathan","Meade-White, Kimberly","Okumura, Atsushi","Callison, Julie","Brumbaugh, Beniah","Avanzato, Victoria A","Rosenke, Rebecca","Hanley, Patrick W","Saturday, Greg","Scott, Dana","Fischer, Elizabeth R","de Wit, Emmie"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396922","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41586-020-2324-7","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666627827804405760,"score":397.4251},{"pmid":32433465,"title":"Immunogenicity of a DNA vaccine candidate for COVID-19.","text":["Immunogenicity of a DNA vaccine candidate for COVID-19.","The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.","Nat Commun","Smith, Trevor R F","Patel, Ami","Ramos, Stephanie","Elwood, Dustin","Zhu, Xizhou","Yan, Jian","Gary, Ebony N","Walker, Susanne N","Schultheis, Katherine","Purwar, Mansi","Xu, Ziyang","Walters, Jewell","Bhojnagarwala, Pratik","Yang, Maria","Chokkalingam, Neethu","Pezzoli, Patrick","Parzych, Elizabeth","Reuschel, Emma L","Doan, Arthur","Tursi, Nicholas","Vasquez, Miguel","Choi, Jihae","Tello-Ruiz, Edgar","Maricic, Igor","Bah, Mamadou A","Wu, Yuanhan","Amante, Dinah","Park, Daniel H","Dia, Yaya","Ali, Ali Raza","Zaidi, Faraz I","Generotti, Alison","Kim, Kevin Y","Herring, Timothy A","Reeder, Sophia","Andrade, Viviane M","Buttigieg, Karen","Zhao, Gan","Wu, Jiun-Ming","Li, Dan","Bao, Linlin","Liu, Jiangning","Deng, Wei","Qin, Chuan","Brown, Ami Shah","Khoshnejad, Makan","Wang, Nianshuang","Chu, Jacqueline","Wrapp, Daniel","McLellan, Jason S","Muthumani, Kar","Wang, Bin","Carroll, Miles W","Kim, J Joseph","Boyer, Jean","Kulp, Daniel W","Humeau, Laurent M P F","Weiner, David B","Broderick, Kate E","32433465"],"abstract":["The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study."],"journal":"Nat Commun","authors":["Smith, Trevor R F","Patel, Ami","Ramos, Stephanie","Elwood, Dustin","Zhu, Xizhou","Yan, Jian","Gary, Ebony N","Walker, Susanne N","Schultheis, Katherine","Purwar, Mansi","Xu, Ziyang","Walters, Jewell","Bhojnagarwala, Pratik","Yang, Maria","Chokkalingam, Neethu","Pezzoli, Patrick","Parzych, Elizabeth","Reuschel, Emma L","Doan, Arthur","Tursi, Nicholas","Vasquez, Miguel","Choi, Jihae","Tello-Ruiz, Edgar","Maricic, Igor","Bah, Mamadou A","Wu, Yuanhan","Amante, Dinah","Park, Daniel H","Dia, Yaya","Ali, Ali Raza","Zaidi, Faraz I","Generotti, Alison","Kim, Kevin Y","Herring, Timothy A","Reeder, Sophia","Andrade, Viviane M","Buttigieg, Karen","Zhao, Gan","Wu, Jiun-Ming","Li, Dan","Bao, Linlin","Liu, Jiangning","Deng, Wei","Qin, Chuan","Brown, Ami Shah","Khoshnejad, Makan","Wang, Nianshuang","Chu, Jacqueline","Wrapp, Daniel","McLellan, Jason S","Muthumani, Kar","Wang, Bin","Carroll, Miles W","Kim, J Joseph","Boyer, Jean","Kulp, Daniel W","Humeau, Laurent M P F","Weiner, David B","Broderick, Kate E"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433465","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41467-020-16505-0","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288138797057,"score":371.06},{"pmid":32318665,"pmcid":"PMC7167234","title":"Age-related rhesus macaque models of COVID-19.","text":["Age-related rhesus macaque models of COVID-19.","Background: Since December 2019, an outbreak of the Corona Virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, has become a public health emergency of international concern. The high fatality of aged cases caused by SARS-CoV-2 was a need to explore the possible age-related phenomena with non-human primate models. Methods: Three 3-5 years old and two 15 years old rhesus macaques were intratracheally infected with SARS-CoV-2, and then analyzed by clinical signs, viral replication, chest X-ray, histopathological changes and immune response. Results: Viral replication of nasopharyngeal swabs, anal swabs and lung in old monkeys was more active than that in young monkeys for 14 days after SARS-CoV-2 challenge. Monkeys developed typical interstitial pneumonia characterized by thickened alveolar septum accompanied with inflammation and edema, notably, old monkeys exhibited diffuse severe interstitial pneumonia. Viral antigens were detected mainly in alveolar epithelial cells and macrophages. Conclusion: SARS-CoV-2 caused more severe interstitial pneumonia in old monkeys than that in young monkeys. Rhesus macaque models infected with SARS-CoV-2 provided insight into the pathogenic mechanism and facilitated the development of vaccines and therapeutics against SARS-CoV-2 infection.","Animal Model Exp Med","Yu, Pin","Qi, Feifei","Xu, Yanfeng","Li, Fengdi","Liu, Peipei","Liu, Jiayi","Bao, Linlin","Deng, Wei","Gao, Hong","Xiang, Zhiguang","Xiao, Chong","Lv, Qi","Gong, Shuran","Liu, Jiangning","Song, Zhiqi","Qu, Yajin","Xue, Jing","Wei, Qiang","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Yu, Haisheng","Liu, Xing","Huang, Baoying","Wang, Wenling","Zhao, Li","Wang, Huijuan","Ye, Fei","Zhou, Weimin","Zhen, Wei","Han, Jun","Wu, Guizhen","Jin, Qi","Wang, Jianwei","Tan, Wenjie","Qin, Chuan","32318665"],"abstract":["Background: Since December 2019, an outbreak of the Corona Virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, has become a public health emergency of international concern. The high fatality of aged cases caused by SARS-CoV-2 was a need to explore the possible age-related phenomena with non-human primate models. Methods: Three 3-5 years old and two 15 years old rhesus macaques were intratracheally infected with SARS-CoV-2, and then analyzed by clinical signs, viral replication, chest X-ray, histopathological changes and immune response. Results: Viral replication of nasopharyngeal swabs, anal swabs and lung in old monkeys was more active than that in young monkeys for 14 days after SARS-CoV-2 challenge. Monkeys developed typical interstitial pneumonia characterized by thickened alveolar septum accompanied with inflammation and edema, notably, old monkeys exhibited diffuse severe interstitial pneumonia. Viral antigens were detected mainly in alveolar epithelial cells and macrophages. Conclusion: SARS-CoV-2 caused more severe interstitial pneumonia in old monkeys than that in young monkeys. Rhesus macaque models infected with SARS-CoV-2 provided insight into the pathogenic mechanism and facilitated the development of vaccines and therapeutics against SARS-CoV-2 infection."],"journal":"Animal Model Exp Med","authors":["Yu, Pin","Qi, Feifei","Xu, Yanfeng","Li, Fengdi","Liu, Peipei","Liu, Jiayi","Bao, Linlin","Deng, Wei","Gao, Hong","Xiang, Zhiguang","Xiao, Chong","Lv, Qi","Gong, Shuran","Liu, Jiangning","Song, Zhiqi","Qu, Yajin","Xue, Jing","Wei, Qiang","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Yu, Haisheng","Liu, Xing","Huang, Baoying","Wang, Wenling","Zhao, Li","Wang, Huijuan","Ye, Fei","Zhou, Weimin","Zhen, Wei","Han, Jun","Wu, Guizhen","Jin, Qi","Wang, Jianwei","Tan, Wenjie","Qin, Chuan"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318665","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ame2.12108","keywords":["sars-cov-2","pathogenicity","pneumonia","rhesus macaque model"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493603020800,"score":367.79327}]}